Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Oral Anti-Viral for Covid-19 Filed under FDA’s CTAP | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Oral Anti-Viral for Covid-19 Filed under FDA’s CTAP

BioSig’s Vicromax is an orally administered drug that could be delivered to patients during all stages of Covid-19

By: Contract Pharma

Contract Pharma Staff

BioSig Technologies, a medical technology company commercializing a proprietary biomedical signal processing platform, has filed for consideration with the FDA under the Coronavirus Treatment Acceleration Program (CTAP) for Vicromax, an orally administered drug that could be delivered to patients during all stages of Covid-19 – early-stage right when the patient starts to feel symptoms, mid-stage, or even late-stage while in the ICU. Earlier in the week, the company announced that the Mayo Clinic will be conducting Phase II trials for Vicromax in patients with Covid-19.    

Vicromax is an oral anti-viral treatment that has shown to have positive effects against the novel Coronavirus. In a laboratory setting at the Galveston National Laboratory in Texas, Vicromax was added to a tissue culture assay for SARS-CO-2 coronavirus and an anti-viral effect was observed, which led to a reduction of 98% of the infectious viruses.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters